Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0254)
Drug Name
Cabozantinib
Synonyms
Cabozantinib; Cabozantinib (XL-184); Cabozantinib (XL184, BMS-907351); Cometriq; Cometriq (TN); XL 184; XL-184; 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-; 1C39JW444G; 849217-68-1; BMS 907351; BMS-907351; BMS907351; C28H24FN3O5; CHEBI:72317; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; UNII-1C39JW444G; XL184; n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
Indication Thyroid cancer [ICD11: 2D10] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 501.5 Topological Polar Surface Area 98.8
Heavy Atom Count 37 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
25102847
PubChem SID
103932275 ; 117695999 ; 131480693 ; 135267839 ; 135626782 ; 135727427 ; 136367316 ; 136368016 ; 136920380 ; 137256574 ; 137276008 ; 137760418 ; 143499870 ; 144115772 ; 152234431 ; 152258418 ; 160647254 ; 160676622 ; 160962864 ; 162011361 ; 162037456 ; 162202657 ; 164023425 ; 164041945 ; 164837657 ; 172914677 ; 174530916 ; 175266754 ; 178102511 ; 185997013 ; 198993077 ; 202543085 ; 223387911 ; 224083495 ; 226693608 ; 244920971 ; 249737079 ; 249896088 ; 252088620 ; 252110119 ; 252158839 ; 252215083 ; 252439619 ; 252451817 ; 252543409
ChEBI ID
CHEBI:72317
CAS Number
849217-68-1
TTD Drug ID
D0IQ6P
Formula
C28H24FN3O5
Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
InChI
1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
InChIKey
ONIQOQHATWINJY-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
4-Fluoroaniline DM000518
9731
Unclear 1 [2]
EXEL-1646 DM000519
86269462
Conjugation - Monohydroxy Sulphation 1 [2]
EXEL-5162 DM000520
78325042
Oxidation - N-Oxidation 1 [2]
EXEL-5366 DM000516
57810164
Unclear 1 [2]
EXEL-1644 DM000517
86269669
Unclear 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000535 Cabozantinib EXEL-5366 Unclear Unclear [2]
MR000536 Cabozantinib 4-Fluoroaniline Unclear Unclear [2]
MR000537 Cabozantinib EXEL-1646 Conjugation - Monohydroxy Sulphation Unclear [2]
MR000538 Cabozantinib EXEL-5162 Oxidation - N-Oxidation CYP3A4 ... [2]
MR000534 EXEL-5366 EXEL-1644 Unclear Unclear [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[4]
References
1 Cabozantinib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib Clin Pharmacokinet. 2017 May;56(5):477-491. doi: 10.1007/s40262-016-0461-9.
3 FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
4 Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.